Molecular Partners (MOLN) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Molecular Partners (MOLN) has outperformed Outlook Therapeutics (OTLK) over the past year, gaining 2.7% versus a loss of 49.6%. Over five years, MOLN leads with a -80.8% price change compared with -98.6% for OTLK. Molecular Partners is the larger company by market cap ($145.9 million vs $143.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MOLN | OTLK |
|---|---|---|
| Share price | $3.81 | $0.59 |
| Market cap | $145.94M | $143.63M |
| 1-day change | +0.79% | +3.15% |
| YTD return | -12.59% | -62.66% |
| 1-year return | +2.70% | -49.57% |
| 5-year return | -80.76% | -98.60% |
| EPS (TTM) | $-1.71 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.36 | $2.54 |
| 52-week low | $3.53 | $0.161 |
| Distance from 52-week high | -28.92% | -76.75% |
| Analyst consensus | none | none |
| Avg. price target upside | +172.18% | +752.54% |
| Average volume | 1.20K | 13.58M |
| Shares outstanding | 38.31M | 243.45M |
| Employees | 134 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed OTLK by 52.3 percentage points over the past year.
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Healthcare · Biotechnology · 134 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Healthcare · Biotechnology · 17 employees
MOLN vs OTLK FAQ
Which is bigger, Molecular Partners or Outlook Therapeutics?
Molecular Partners (MOLN) is larger, with a market capitalization of $145.94M compared with $143.63M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, MOLN or OTLK?
MOLN returned +2.70% over the past 12 months, compared with -49.57% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Molecular Partners and Outlook Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.